{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:53:35Z","timestamp":1785876815696,"version":"3.56.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,29]],"date-time":"2027-07-29T00:00:00Z","timestamp":1816819200000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017618","name":"NIDDK Division of Diabetes Endocrinology and Metabolic Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.015","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:25:33Z","timestamp":1781220333000},"page":"495-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide\/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes"],"prefix":"10.1016","volume":"55","author":[{"given":"Michael S.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Pasquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib1","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165654","article-title":"Molecular pathways that drive diabetic kidney disease","volume":"133","author":"Mohandes","year":"2023","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ecl.2026.04.015_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2026.1747053","article-title":"Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease","volume":"17","author":"Al-Masri","year":"2026","journal-title":"Front Physiol"},{"key":"10.1016\/j.ecl.2026.04.015_bib3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","article-title":"AGE\/RAGE in diabetic kidney disease and ageing kidney","volume":"171","author":"Wu","year":"2021","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib4","first-page":"1059","article-title":"Signaling pathways in diabetic nephropathy","volume":"31","author":"Kawanami","year":"2016","journal-title":"Histol Histopathol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib5","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.2337\/dc20-3097","article-title":"Understanding metabolic memory: the prolonged influence of glycemia during the diabetes control and complications trial (DCCT) on future risks of complications during the study of the epidemiology of diabetes interventions and complications (EDIC)","volume":"44","author":"Lachin","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2337\/diabetes.55.04.06.db05-1619","article-title":"Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes","volume":"55","author":"Nieuwdorp","year":"2006","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.015_bib7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.2337\/db07-0019","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy","volume":"56","author":"Toyoda","year":"2007","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.015_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2024.02.025","article-title":"The key role of altered tubule cell lipid metabolism in kidney disease development","volume":"106","author":"Lee","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ecl.2026.04.015_bib9","article-title":"Inflammatory cytokines in diabetic kidney disease: Pathophysiologic and therapeutic implications","volume":"7","author":"Donate-Correa","year":"2020","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib10","doi-asserted-by":"crossref","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","article-title":"Effect of aldosterone on renal transforming growth factor-beta","volume":"286","author":"Juknevicius","year":"2004","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ecl.2026.04.015_bib11","article-title":"A glimpse of inflammation and anti-inflammation therapy in diabetic kidney disease","volume":"13","author":"Liu","year":"2022","journal-title":"Front Physiol"},{"issue":"19","key":"10.1016\/j.ecl.2026.04.015_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.015_bib14","doi-asserted-by":"crossref","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton","year":"2018","journal-title":"Am J Physiol Ren Physiol"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.015_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: mechanisms beyond tubuloglomerular feedback","volume":"5","author":"Upadhyay","year":"2024","journal-title":"Kidney360"},{"issue":"24","key":"10.1016\/j.ecl.2026.04.015_bib16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ecl.2026.04.015_bib17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.015_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis","volume":"335","author":"Neuen","year":"2026","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jama.2025.20835","article-title":"Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis","volume":"335","author":"Staplin","year":"2026","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.015_bib21","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.015_bib22","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-Week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib23","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib24","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.015_bib25","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metabol"},{"issue":"24","key":"10.1016\/j.ecl.2026.04.015_bib27","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib28","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib29","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA(1c) and hypoglycemia reductions at 24 and 52 weeks with Sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib30","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2337\/dc18-1983","article-title":"Glucose variables in type 1 diabetes studies with dapagliflozin: pooled analysis of continuous glucose monitoring data from DEPICT-1 and -2","volume":"42","author":"Mathieu","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.015_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.07700621","article-title":"Kidney effects of empagliflozin in people with type 1 diabetes","volume":"16","author":"Cherney","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib33","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.015_bib34","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc23-0129","article-title":"The effects of sotagliflozin in type 1 diabetes on clinical markers associated with cardiorenal protection: an exploratory analysis of inTandem3","volume":"46","author":"Sridhar","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.015_bib56","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib59","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in type 1 diabetes and chronic kidney disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.015_bib35","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41591-025-03723-6","article-title":"Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial","volume":"31","author":"Mahmud","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ecl.2026.04.015_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110794","article-title":"Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: a retrospective multicenter study of the KAMOGAWA-A cohort","volume":"202","author":"Hironaka","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib37","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc21-1584","article-title":"Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: a European two-center experience","volume":"45","author":"Palanca","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib38","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/dom.16329","article-title":"Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: a real world analysis","volume":"27","author":"Tsur","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib39","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.ecl.2026.04.015_bib40","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/jama.2024.18581","article-title":"GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes","volume":"332","author":"Li","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.015_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ecl.2026.04.015_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194749","article-title":"GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity","volume":"135","author":"Cooper","year":"2025","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib44","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","article-title":"Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells","volume":"297","author":"Carraro-Lacroix","year":"2009","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.015_bib45","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Ren Physiol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.015_bib46","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1152\/ajprenal.00394.2015","article-title":"The physiological role of glucagon-like peptide-1 in the regulation of renal function","volume":"310","author":"Farah","year":"2016","journal-title":"Am J Physiol Ren Physiol"},{"issue":"19","key":"10.1016\/j.ecl.2026.04.015_bib47","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib48","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.ecl.2026.04.015_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.015_bib50","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2026.04.015_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2026.0767","article-title":"Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial","author":"Nissen","year":"2026","journal-title":"JAMA Cardiol"},{"issue":"20","key":"10.1016\/j.ecl.2026.04.015_bib52","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ndt\/gfaf193","article-title":"The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis","volume":"41","author":"Sasaki","year":"2026","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib79","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.015_bib80","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: rhe ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib78","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/dia.2024.0481","article-title":"Cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes treated with tirzepatide for 21 months","volume":"27","author":"Garg","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib54","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2215\/CJN.13541021","article-title":"Hyperkalemia with mineralocorticoid receptor antagonist use in people with CKD: understanding and mitigating the risks","volume":"17","author":"Epstein","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.ecl.2026.04.015_bib57","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ecl.2026.04.015_bib58","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib60","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1523-1755.2004.00524.x","article-title":"Plasma aldosterone concentration in the patient with diabetes mellitus","volume":"65","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.015_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154164","article-title":"Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx","volume":"8","author":"Crompton","year":"2023","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","article-title":"The endothelial glycocalyx: composition, functions, and visualization","volume":"454","author":"Reitsma","year":"2007","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.015_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","article-title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis","volume":"12","author":"Luther","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.015_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145946","article-title":"Aldosterone induces renal fibrosis and inflammatory M1-Macrophage subtype via mineralocorticoid receptor in rats","volume":"11","author":"Mart\u00edn-Fern\u00e1ndez","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib65","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"9068","key":"10.1016\/j.ecl.2026.04.015_bib66","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID study group","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.015_bib67","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ndt\/16.4.771","article-title":"Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM","volume":"16","author":"Buter","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1016\/j.ecl.2026.04.015_bib68","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.015_bib69","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.015_bib70","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/jpm16030156","article-title":"Beyond glycemia: pharmacology-driven ketogenesis and euglycemic DKA with SGLT2 inhibitors-a practical review for acute care","volume":"16","author":"Meco","year":"2026","journal-title":"J Pers Med"},{"key":"10.1016\/j.ecl.2026.04.015_bib71","article-title":"Comparison of protocols to reduce diabetic ketoacidosis in patients with type 1 diabetes prescribed a sodium\u2013glucose cotransporter 2 inhibitor","author":"Teng","year":"2020","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.ecl.2026.04.015_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/15209156261420167","article-title":"Continuous ketone monitoring captures overt ketosis in type 1 diabetes caused by Empagliflozin, low-carbohydrate diet, and exercise","author":"Lawton","year":"2026","journal-title":"Diabetes Technol Therapeut"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.015_bib73","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.gastro.2015.05.007","article-title":"Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus","volume":"149","author":"Bharucha","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.015_bib74","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s13300-024-01592-9","article-title":"Changes in basal and bolus insulin requirements with tirzepatide as an adjunctive therapy in adults with type 1 diabetes using Tandem Control-IQ","volume":"15","author":"Karakus","year":"2024","journal-title":"Diabetes Ther"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.015_bib75","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.cgh.2022.07.011","article-title":"Epidemiology and healthcare utilization in patients with gastroparesis: a systematic review","volume":"21","author":"Dilmaghani","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.015_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.360","article-title":"Potassium management with finerenone: practical aspects","volume":"5","author":"Wanner","year":"2022","journal-title":"Endocrinol Diabetes Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:38:05Z","timestamp":1785875885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000381"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.015","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide\/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}